ArticlePloS one2010
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- DrugPTM-Bench: A Large-Scale Dataset for Predictive Modeling of Drug-Induced Cell Type-Specific Protein Post-Translational Modifications.bioRxiv : the preprint server for biology · 2026Article
- Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2023Review
- Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.Exploration of targeted anti-tumor therapy · 2021Review
- Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples.Frontiers in oncology · 2020Article
- Proteomics-inspired precision medicine for treating and understanding multiple myeloma.Expert review of precision medicine and drug development · 2020Article
- Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network.BMC bioinformatics · 2019Article
- Article
- The Role of the Multifunctional BAG3 Protein in Cellular Protein Quality Control and in Disease.Frontiers in molecular neuroscience · 2017Review
- Proteomic analysis for finding serum pathogenic factors and potential biomarkers in multiple myeloma.Chinese medical journal · 2015Article
- A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.Cellular oncology (Dordrecht, Netherlands) · 2014Article
- 14-3-3 protein targets misfolded chaperone-associated proteins to aggresomes.Journal of cell science · 2013Article
- Translating mRNAs strongly correlate to proteins in a multivariate manner and their translation ratios are phenotype specific.Nucleic acids research · 2013Article
- A new prospect in cancer therapy: targeting cancer stem cells to eradicate cancer.Chinese journal of cancer · 2012Review
- Inhibition of stathmin1 accelerates the metastatic process.Cancer research · 2012Article
- Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.Leukemia · 2012Review
- Characterization of the Phosphoproteome in SLE Patients.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. METHODOLOGY/PRINCIPAL
findingsWe investigated the differential phosphoproteome upon proteasome inhibition by using stable isotope labeling by amino acids in cell culture (SILAC) in combination with phosphoprotein enrichment and LC-MS/MS analysis. In total 233 phosphoproteins were identified and 72 phosphoproteins showed a 1.5-fold or greater change upon bortezomib treatment. The phosphoproteins with expression alterations encompass all major protein classes, including a large number of nucleic acid binding proteins. Site-specific phosphopeptide quantitation revealed that Ser38 phosphorylation on stathmin increased upon bortezomib treatment, suggesting new mechanisms associated to bortezomib-induced apoptosis in MM cells. Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib. CONCLUSIONS/SIGNIFICANCE: Our systematic profiling of phosphorylation changes in response to bortezomib treatment not only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified previously uncharacterized signaling proteins in myeloma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.